Abeona Therapeutics Inc. filed 2 current reports with the SEC under Item 5.02, which covers directors and officers leaving or being appointed, the latest on 2026-06-12. Between them they name 2 people, with 2 appointments and 2 departures. Each change below is quoted from the filing and linked to it.
Every change, newest first
Departing: Michael Amoroso, Director
On June 11, 2026, Michael Amoroso resigned as a member of the Board of Directors (the "Board") of Abeona Therapeutics Inc. (the "Company") effective immediately.
Departing: Michael Amoroso
In connection with his resignation, Mr. Amoroso also resigned from the Nominating and Corporate Governance Committee of the Board on which he served.
Appointed: Keith A. Goldan, Director
On April 1, 2026, the Board of Directors (the "Board") of Abeona Therapeutics Inc. (the "Company"), acting upon the recommendation of its Nominating and Corporate Governance Committee, expanded the size of the Board from nine to ten members and appointed Keith A. Goldan as a member of the Board of the Company as a Class 1 director.
Appointed: Keith A. Goldan
The Board also appointed Mr. Goldan to serve as Chair of the Audit Committee.
Find people with the same kind of experience as the Director at Abeona Therapeutics Inc., with the record behind each one.
Find candidates like Director at Abeona Therapeutics Inc.New leaders review vendors and budgets in their first months. Get an alert the next time Abeona Therapeutics Inc. is in the news or changes leadership.
Get an alert when Abeona Therapeutics Inc. changes leadershipTools for this story
Each opens in a new tab, filled in for Abeona Therapeutics Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
A public company must file a current report on Form 8-K with the SEC within four business days when a director leaves or is elected, or when its chief executive, chief financial, chief accounting or chief operating officer, or another named executive, departs or is appointed. That disclosure goes under Item 5.02 of the report.
Every change on this page is taken from one of those filings and quoted in the company's own words, with a link to the filing, so it can be checked at the source. Where a filing names the person, the role and the date a change takes effect, they are shown beside the quote. Where it does not, the quote stands on its own. A filing states what changed; it rarely states why, and neither does this page.